On this page
RUNX2
RUNX family transcription factor 2
The RUNX2 gene is essential for normal bone and tooth development, providing instructions for a protein that acts as a key regulator of bone-forming cell differentiation. RUNX2 codes for a transcription factor critical for skeletal and dental formation and maintenance.
RUNX2 is located on the short (p) arm of chromosome 6, at band 6p21.1. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 6 in the library →Available at Jeen Health
Clinical tests that include this
Overview
The RUNX2 gene, also known as RUNX family transcription factor 2, plays a vital role in skeletal and dental biology. It controls the development and maintenance of bones, teeth, and cartilage, which is a connective tissue forming much of the early skeleton [PMID:17006093]. The protein encoded by RUNX2 functions as a transcription factor, meaning it binds to specific DNA regions to regulate the expression of other genes involved in bone formation.
Dysregulation of RUNX2 can lead to a variety of inherited conditions that primarily affect the skeleton and teeth. Its designation as a 'master switch' highlights its importance in orchestrating the complex processes of ossification, where cartilage is converted into bone, and the differentiation of osteoblasts, the cells responsible for building new bone tissue.
What the gene does
The RUNX2 gene provides instructions for creating a protein that acts as a transcription factor, centrally involved in the intricate processes of bone and tooth development [PMID:15610816]. This protein binds to specific DNA sequences, thereby controlling the activation or suppression of various genes critical for skeletal morphogenesis.
Its primary function includes regulating the differentiation and maturation of osteoblasts, the specialised cells that synthesise bone matrix and are crucial for bone formation [PMID:11932304]. Furthermore, the RUNX2 protein facilitates the process of ossification, where cartilage is systematically replaced by bone during development, and contributes to the overall maintenance of bone tissue in adults. It is also implicated in the development of teeth, underscoring its broad influence across calcified tissues in the body.
Video: Genetics 101
Chromosome location
The RUNX2 gene is situated on chromosome 6, specifically at position 6p21.1. This genomic location refers to the short arm (p) of chromosome 6, within region 21.1. The gene spans a significant segment of this chromosomal region, contributing to its role in dictating the body's skeletal development architecture.
Protein structure
The RUNX2 protein consists of 521 amino acids and features several distinct functional regions and domains. An N-terminal Disordered region is found between amino acids 18-59. The highly conserved Runt domain, critical for DNA binding and protein-protein interactions, spans amino acids 101-229. Following this, another Disordered region is present from amino acids 222-340.
A specific region from amino acids 242-258 is required for interaction with the FOXO1 protein, indicating its role in diverse cellular pathways. Additional interaction domains include one for KAT6A, located between amino acids 336-439, and another for KAT6B, found from amino acids 374-468. The protein concludes with a C-terminal Disordered region spanning amino acids 460-521.
Key variants
Variations within the RUNX2 gene can significantly influence its function, leading to a spectrum of health outcomes. These genetic changes can range from single nucleotide substitutions, altering a single protein building block, to larger deletions or duplications of genetic material. Some variants may introduce premature stop signals, resulting in abnormally short and non-functional proteins, while others might alter key domains, affecting DNA binding or protein interactions.
The clinical impact of a RUNX2 variant depends on its specific nature and location, potentially disrupting proper bone and tooth development. Genetic testing can identify these variants, providing insight into an individual's genetic predisposition to associated conditions.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.1085C>T | p.Ala362Val | Pathogenic | ★★☆☆ | not provided |
c.1171C>T | p.Arg391Ter | Pathogenic | ★★☆☆ | Cleidocranial dysostosis |
c.1379dup | p.Asp463fs | Pathogenic/Likely pathogenic | ★★☆☆ | not provided |
c.1385dup | p.Asp463fs | Pathogenic/Likely pathogenic | ★★☆☆ | RUNX2-related disorder |
c.476G>A | p.Gly159Asp | Pathogenic/Likely pathogenic | ★★☆☆ | Cleidocranial dysostosis |
c.505C>T | p.Arg169Trp | Pathogenic/Likely pathogenic | ★★☆☆ | not provided |
c.568C>T | p.Arg190Trp | Pathogenic | ★★☆☆ | Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome |
c.569G>A | p.Arg190Gln | Pathogenic | ★★☆☆ | Cleidocranial dysostosis |
c.577C>T | p.Arg193Ter | Pathogenic | ★★☆☆ | Cleidocranial dysostosis |
c.578G>A | p.Arg193Gln | Pathogenic/Likely pathogenic | ★★☆☆ | Cleidocranial dysostosis |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Variants in the RUNX2 gene are primarily associated with conditions affecting bone and tooth development. The most well-characterised condition linked to RUNX2 variants is Cleidocranial dysplasia, an autosomal dominant disorder affecting skeletal formation, particularly the clavicles and skull. Additionally, duplications of segments within the RUNX2 gene can lead to conditions such as metaphyseal dysplasia, maxillary hypoplasia, and brachydactyly (MDMHB), which involves abnormalities in long bones, the upper jaw, and fingers.
Inheritance pattern
Conditions caused by pathogenic RUNX2 variants typically follow autosomal dominant inheritance.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
UK clinical status
In the UK, the RUNX2 gene is recognised on several NHS Genomic Medicine Service national test directories, indicating its clinical significance. It is listed as 'green' on PanelApp under Cleidocranial Dysplasia (R415), Foetal anomalies (R21), Rare syndromic craniosynostosis or isolated multisuture synostosis (R100), and Skeletal dysplasia (R104) panels. This status signifies that there is strong evidence for the gene's association with these conditions, and it is routinely tested in relevant clinical contexts within NHS laboratories.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Diet & lifestyle considerations
Maintaining general bone health through lifestyle choices can be beneficial for the wider population, though it does not prevent genetic conditions associated with RUNX2 variants. Regular weight-bearing exercise is generally recommended to support bone density. A balanced diet rich in calcium and vitamin D is also advised, as these nutrients are crucial for bone metabolism. Avoiding smoking and excessive alcohol consumption contributes to overall skeletal well-being. These general health recommendations are for the population and should not be interpreted as specific treatments for genetic disorders.
Supplement considerations
While certain supplements, such as calcium and vitamin D, are widely recognised for their role in bone health, there is no conclusive evidence that they can prevent or directly treat inherited conditions caused by RUNX2 gene variants. These supplements support the general bone maintenance processes in the wider population. Individuals considering any supplements should consult a healthcare provider to ensure they are appropriate for their specific health needs and do not interact with existing medications. Self-medication is not advisable for genetic conditions.
Frequently asked questions
What is the primary function of the RUNX2 gene?
The RUNX2 gene provides instructions for a protein that acts as a transcription factor, primarily responsible for regulating the development and maintenance of bones, teeth, and cartilage, especially by controlling osteoblast differentiation.
Which condition is most commonly associated with RUNX2 variants?
The condition most commonly associated with variants in the RUNX2 gene is Cleidocranial dysplasia, an inherited disorder characterised by abnormalities in bone formation, particularly affecting the collarbones and skull.
Is RUNX2 testing available in the UK NHS?
Yes, testing for the RUNX2 gene is part of several NHS Genomic Medicine Service national test directories in the UK, indicated by its 'green' status on PanelApp for conditions like Cleidocranial Dysplasia and Skeletal dysplasia.
What does it mean for RUNX2 to be a 'master switch'?
Referring to RUNX2 as a 'master switch' highlights its critical role in initiating and coordinating the expression of numerous other genes essential for the development of bone-forming cells (osteoblasts) and the overall process of ossification.
Can lifestyle changes prevent conditions caused by RUNX2 variants?
While a healthy lifestyle with adequate calcium and vitamin D, along with regular exercise, supports general bone health, it is not known to prevent or cure genetic conditions directly caused by variants in the RUNX2 gene.
References
- Dinçsoy Bir F, Dinçkan N, Güven Y. Cleidocranial dysplasia: Clinical, endocrinologic and molecular findings in 15 patients from 11 families. European journal of medical genetics. 2017. PMID: 28027977
- Jaruga A, Hordyjewska E, Kandzierski G. Cleidocranial dysplasia and RUNX2-clinical phenotype-genotype correlation. Clinical genetics. 2016. PMID: 27272193
- Wysokinski D, Pawlowska E, Blasiak J. RUNX2: A Master Bone Growth Regulator That May Be Involved in the DNA Damage Response. DNA and cell biology. 2015. PMID: 25555110
- Vimalraj S, Arumugam B, Miranda PJ. Runx2: Structure, function, and phosphorylation in osteoblast differentiation. International journal of biological macromolecules. 2015. PMID: 25881954
- Avela K, Hirvinen H, Ben Amor M. Metaphyseal dysplasia with maxillary hypoplasia and brachydactyly in a Finnish woman: first confirmation of a duplication in RUNX2 as pathogenic variant. European journal of medical genetics. 2014. PMID: 25311905
- Bruderer M, Richards RG, Alini M. Role and regulation of RUNX2 in osteogenesis. European cells & materials. 2014. PMID: 25340806
- Moffatt P, Ben Amor M, Glorieux FH. Metaphyseal dysplasia with maxillary hypoplasia and brachydactyly is caused by a duplication in RUNX2. American journal of human genetics. 2013. PMID: 23290074
- Cohen MM Jr. Biology of RUNX2 and Cleidocranial Dysplasia. The Journal of craniofacial surgery. 2013. PMID: 23348269
- Bufalino A, Paranaíba LM, Gouvêa AF. Cleidocranial dysplasia: oral features and genetic analysis of 11 patients. Oral diseases. 2012. PMID: 22023169
- D'Alessandro G, Tagariello T, Piana G. Cleidocranial dysplasia: etiology and stomatognathic and craniofacial abnormalities. Minerva stomatologica. 2010. PMID: 20357738
- Adam MP, Bick S, Mirzaa GM. Cleidocranial Dysplasia Spectrum Disorder. 1993. PMID: 20301686